Evaluation of Apolipoprotein A5 Polymorphism in Coronary- Heart Disease Patients

Apolipoprotein A5 (APOA5) gene is important in determining plasma triglyceride levels, a major cardiovascular disease risk factor. Mutation in this gene affected plasma triglyceride level. We looked for possible associations of the APOA5 gene polymorphism S19W with coronary heart disease (CHD) in a sample of Iranian population.

A total of 73 CHD patients and 55 controls were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) for this single nucleotide polymorphism. Serum lipids and Fast Blood Sugar concentrations were measured in all subjects with enzymatic method.

Allele frequencies observed in our population were 0.041 for the W allele and 0.959 for the S allele which are similar to other populations (p>0.05). There is no evidence that APOA5 S19W, is a risk factor of CHD in our sample (p>0.05). In addition, we observed no association between the APOA5 W allele and elevated plasma TG levels (p>0.05) in the CHD group. This result was also present in the control group (p>0.05).

The APO A5 gene polymorphism in S19W gene has no association with the high susceptibility to CHD.